154 related articles for article (PubMed ID: 21607771)
1. Pioglitazone, etoricoxib, interferon-α, and metronomic capecitabine for metastatic renal cell carcinoma: final results of a prospective phase II trial.
Walter B; Schrettenbrunner I; Vogelhuber M; Grassinger J; Bross K; Wilke J; Suedhoff T; Berand A; Wieland WF; Rogenhofer S; Andreesen R; Reichle A
Med Oncol; 2012 Jun; 29(2):799-805. PubMed ID: 21607771
[TBL] [Abstract][Full Text] [Related]
2. Phase II, multicenter, uncontrolled trial of single-agent capecitabine in patients with non-clear cell metastatic renal cell carcinoma.
Tsimafeyeu I; Demidov L; Kharkevich G; Petenko N; Galchenko V; Sinelnikov I; Naidzionak U
Am J Clin Oncol; 2012 Jun; 35(3):251-4. PubMed ID: 21358295
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of capecitabine single-agent therapy in patients with metastatic renal cell carcinoma.
Pagliaro LC; Perez CA; Tu SM; Daliani DD
Urol Oncol; 2006; 24(6):487-91. PubMed ID: 17138128
[TBL] [Abstract][Full Text] [Related]
4. Modular therapy approach in metastatic castration-refractory prostate cancer.
Walter B; Rogenhofer S; Vogelhuber M; Berand A; Wieland WF; Andreesen R; Reichle A
World J Urol; 2010 Dec; 28(6):745-50. PubMed ID: 20490506
[TBL] [Abstract][Full Text] [Related]
5. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).
Bellmunt J; Trigo JM; Calvo E; Carles J; Pérez-Gracia JL; Rubió J; Virizuela JA; López R; Lázaro M; Albanell J
Lancet Oncol; 2010 Apr; 11(4):350-7. PubMed ID: 20163987
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of capecitabine and rHu-interferon-alpha-2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity.
Segota E; Mekhail T; Olencki T; Hutson TE; Dreicer R; Wacker B; Osterwalder B; Elson P; Zhou M; Bukowski RM
Urol Oncol; 2007; 25(1):46-52. PubMed ID: 17208138
[TBL] [Abstract][Full Text] [Related]
7. Capecitabine monotherapy and in combination with immunotherapy in the treatment of metastatic renal cell carcinoma.
Wenzel C; Locker GJ; Bartsch R; Pluschnig U; Mader R; Hussian D; Kramer G; Marberger M; Lintner C; Rauchenwald M; Zielinski CC; Steger GG
Anticancer Drugs; 2003 Nov; 14(10):779-84. PubMed ID: 14597871
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with capecitabine and interferon alfa-2A in patients with advanced renal cell carcinoma: a phase II study.
Padrik P; Leppik K; Arak A
Urol Oncol; 2004; 22(5):387-92. PubMed ID: 15464918
[TBL] [Abstract][Full Text] [Related]
9. A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
Tagawa ST; Milowsky MI; Jeske S; Mazumdar M; Kung S; Sung M; Lehrer D; Matulich D; Selzer J; Wright JJ; Nanus DM
Am J Clin Oncol; 2011 Oct; 34(5):443-8. PubMed ID: 20881475
[TBL] [Abstract][Full Text] [Related]
10. A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancer.
Sunela KL; Koskinen S; Kellokumpu-Lehtinen PL
Cancer Chemother Pharmacol; 2010 May; 66(1):59-67. PubMed ID: 19771431
[TBL] [Abstract][Full Text] [Related]
11. A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma.
Amato RJ; Khan M
Cancer Chemother Pharmacol; 2008 May; 61(6):1069-73. PubMed ID: 17701037
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of metastatic renal cell carcinoma with oral capecitabine and thalidomide.
Kraemer A; Hauser S; Kim Y; Gorschlüter M; Müller SC; Brossart P; Schmidt-Wolf IG
Ger Med Sci; 2009 Jun; 7():Doc04. PubMed ID: 19675744
[TBL] [Abstract][Full Text] [Related]
13. A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents.
Tannir NM; Thall PF; Ng CS; Wang X; Wooten L; Siefker-Radtke A; Mathew P; Pagliaro L; Wood C; Jonasch E
J Urol; 2008 Sep; 180(3):867-72; discussion 872. PubMed ID: 18635226
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of capecitabine and weekly docetaxel in metastatic renal cell carcinoma.
Marur S; Eliason J; Heilbrun LK; Dickow B; Smith DW; Baranowski K; Alhasan S; Vaishampayan U
Urology; 2008 Oct; 72(4):898-902. PubMed ID: 18692873
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma.
Rini BI; Weinberg V; Small EJ
Cancer; 2005 Feb; 103(3):553-8. PubMed ID: 15612026
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of capecitabine in combination with interferon alpha in patients with metastatic renal cancer: toxicity and pharmacokinetics.
Chang DZ; Olencki T; Budd GT; Peereboom D; Ganapathi R; Osterwalder B; Bukowski R
Cancer Chemother Pharmacol; 2001 Dec; 48(6):493-8. PubMed ID: 11800031
[TBL] [Abstract][Full Text] [Related]
17. Interferon-alpha plus capecitabine and thalidomide in patients with metastatic renal cell carcinoma: a pilot study.
Amato RJ; Rawat A
Invest New Drugs; 2006 May; 24(3):171-5. PubMed ID: 16086096
[TBL] [Abstract][Full Text] [Related]
18. Interferon-alpha plus capecitabine and thalidomide in patients with metastatic renal cell cancer.
Amato RJ; Mohammad T
J Exp Ther Oncol; 2008; 7(1):41-7. PubMed ID: 18472641
[TBL] [Abstract][Full Text] [Related]
19. Capecitabine in the treatment of metastatic renal cell carcinoma.
Oevermann K; Buer J; Hoffmann R; Franzke A; Schrader A; Patzelt T; Kirchner H; Atzpodien J
Br J Cancer; 2000 Sep; 83(5):583-7. PubMed ID: 10944596
[TBL] [Abstract][Full Text] [Related]
20. The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer.
Harshman LC; Li M; Srinivas S
Am J Clin Oncol; 2008 Oct; 31(5):417-23. PubMed ID: 18838876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
